help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0727
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/9/3471    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mamanasiri, S.
Right arrow Articles by Refetoff, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mamanasiri, S.
Right arrow Articles by Refetoff, S.
Related Collections
Right arrow Pediatric Endocrinology
Right arrow Thyroid
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 9 3471-3477
Copyright © 2006 by The Endocrine Society

Mosaicism of a Thyroid Hormone Receptor-ß Gene Mutation in Resistance to Thyroid Hormone

Sunee Mamanasiri, Sena Yesil, Alexandra M. Dumitrescu, Xiao-Hui Liao, Tevfik Demir, Roy E. Weiss and Samuel Refetoff

Departments of Medicine (S.M., A.M.D., X.-H.L., R.E.W., S.R.) and Pediatrics (S.R.) and Committees on Genetics (S.R.) and Molecular Medicine (S.R., R.E.W.), The University of Chicago, Chicago, Illinois 60637; and Division of Endocrinology (S.Y., T.D.), Dokuz Eylül University, TR-35240 Izmir, Turkey

Address all correspondence and requests for reprints to: Samuel Refetoff, University of Chicago, MC 3090, 5841 South Maryland Avenue, Chicago, Illinois 60637. E-mail: refetoff{at}uchicago.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: Heterozygous mutations in thyroid hormone receptor-ß (TRß) gene are the cause of resistance to thyroid hormone (RTH) in more than 85% of families having the syndrome. In 23% of the families, TRß gene mutations occur de novo. Of the 141 families with RTH investigated by us, 21 (15%) had no TRß gene mutations detectable by sequencing from genomic DNA (gDNA) or cDNA (non-TR RTH).

Objective: The objective of the study was to investigate the genotype of a family with RTH and correlate it to the phenotype.

Design: The DNA was isolated from different tissues, and the sequence of the TRß gene was determined. Clinical studies involved the administration of incremental doses of T3.

Setting: The study was conducted at a referral pediatric endocrinology clinic in Turkey and an academic medical center in the United States.

Main Outcome and Measures: Measurement included markers of thyroid hormone action and sequencing of TRß revealing a R338W mutation.

Patients and Family: We studied two siblings with short stature, panic disorder, psychosis, and high free iodothyronine concentrations with nonsuppressed TSH and their father with similar thyroid function tests without growth or psychiatric abnormalities.

Results: Direct sequencing of gDNA obtained from the father’s leukocytes, buccal mucosa cells, and prostate tissue showed less amplification of the mutant allele (R338W) than the normal allele as confirmed by PCR/restriction fragment length polymorphism analysis. No sequence abnormalities were detected in gDNA from fibroblasts. Similar results were found in mRNA from the leukocytes and fibroblasts. The sensitivity of various tissues to thyroid hormone was not uniform. The progeny had equal amounts of mutant and wild-type gDNA in leukocytes and skin.

Conclusions: The father has a mosaicism for the R338W mutation as it was present in some cell lineages, including his germline, because it was transferred to his children but not in fibroblasts. This indicates that the mutation occurred de novo in early embryonic life. Here is the first report of mosaicism in RTH. The possibility of mosaicism should be considered in subjects with RTH without apparent mutations in the TRß gene.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
RESISTANCE TO thyroid hormone (RTH), first described by Refetoff et al. in 1967 (1), is a syndrome of reduced responsiveness of target tissues to thyroid hormone (2). Clinically these patients are identified by their persistent elevation of circulating free T4 (FT4) and free T3 levels with persistent normal or slightly elevated serum TSH. The phenotype is heterogeneous. The most common clinical findings are goiter, learning disabilities with or without hyperactive behavior, developmental delay, and sinus tachycardia (2, 3, 4, 5). The variability in clinical manifestations may be due to the severity of the hormonal resistance, effectiveness of compensatory mechanisms, modulating genetic factors, and effects of prior therapy (2, 5, 6).

Linkage between RTH and the thyroid hormone receptor (TR)-ß gene was shown in 1988 (7). Since then, more than 300 families with the RTH phenotype have been found to harbor mutations in that gene (2). RTH is usually transmitted in an autosomal dominant fashion, but de novo cases are common, and recessive inheritance is rare (8). In our laboratory de novo mutations occurred in 22.5% of the 120 families in which TRß gene mutations were excluded in the parents of an affected individual (2); 44.4% of the de novo mutations occurred in mutagenic CpG dinucleotide hot spots. The mutant TRß molecules have either a reduced affinity for T3 (6, 9) or impaired interaction with one of the cofactors involved in the mediation of thyroid hormone action (10, 11).

However, RTH can occur in the absence of mutations in the TR{alpha} or TRß gene and is referred to as non-TR RTH. Since the first demonstration of non-TR RTH (12), 29 subjects belonging to 23 different families have been identified (2, 13, 14, 15). The phenotype is indistinguishable from that in subjects harboring TRß gene mutations. Distinct features are an increased female to male ratio of 2.5:1 and the high prevalence of sporadic cases (2, 13). In only three families had linkage analysis excluded the involvement of the TRß gene (12, 16).

Although not previously reported, the variable presence of a TRß mutation in certain tissues may present as non-TR RTH, depending on the tissue analyzed for the TRß mutation in a subject with RTH. We report for the first time the occurrence of mosaicism in RTH that might be misdiagnosed as non-TR RTH. The affected individual had variable tissue expression of the de novo TRß gene mutation, R338W, which was transmitted to his children.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects

The proposita (II.1), a 36-yr-old Turkish woman, presented with a multinodular goiter, short stature (144 cm), and a depressive disorder. She had serum free T3 of 5.83 pg/ml (1.57–4.71), FT4 of 4.23 ng/dl (0.8–1.9), and TSH of 1.21 µIU/ml (0.4–5), increased thyroidal radioiodide uptake of 52.5% at 24 h, but positive thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies, and normal pituitary magnetic resonance imaging. Her 32-yr-old brother (II.2) was agitated and had evidence of psychosis. He had similar abnormal thyroid function tests (TFTs) and antibodies. Blood samples were obtained from all family members. We found that the father (I.1) also had abnormal TFTs (Fig. 1Go), whereas the mother (I.2) had only positive TPO and TG antibodies. The father had normal growth and no psychological problems. Informed consents were obtained for this study approved by the Institutional Review Board of the University of Chicago.


Figure 1
View larger version (22K):
[in this window]
[in a new window]
  		FIG. 1. Pedigree of the family and results of thyroid function tests. AITD, Autoimmune thyroid disease. Proposita, arrow. Conversion to SI: TT4 (nanomoles per liter) and FT4I, multiply by 12.84; total T3 (TT3) and TrT3 (nanomoles per liter), multiply by 0.0154.

 
Measurement of hormones in serum

Total thyroxine (TT4), total T3, and TSH were measured by chemiluminescence using Elecsys 2010 technology (Roche Molecular Biochemicals GmbH and Hitachi, Ltd., both located in Indianapolis, IN). Total reverse T3 (TrT3) and TG were measured by RIAs. FT4 index (FT4I) was estimated from the resin T4 uptake ratio and the TT4 concentrations. TPO and TG antibodies were measured by an agglutination method.

Clinical studies

To assess the sensitivity of various tissues to thyroid hormone, the father was given incremental doses of L-T3 (50, 100, and 200 µg/d, each for 3 consecutive days). L-T3 was administered orally as a split dose, every 12 h, for a total of six doses per incremental dose (3). Just before beginning the study and 12 h after the last of each incremental dose, blood was drawn for the determination of the hormonal measurements described above as well as for the measurement of serum cholesterol, creatine kinase (CK), ferritin, and SHBG. In addition, body weight and resting pulse rate were recorded. Fifteen healthy volunteers served as controls.

Sequencing of the TRß gene

Genomic DNA (gDNA) was extracted from peripheral blood lymphocytes (PBLs) of the proposita and members of her family. A second blood sample was drawn from the father. In addition, primary cultures of fibroblasts were generated from skin punch biopsies obtained from the proposita and her father. Additional tissues examined were buccal mucosa cells and prostate tissue obtained for diagnostic purposes unrelated to this study. Total RNA was extracted from skin of proposita, her father’s PBLs, and cultured skin fibroblasts (17).

All coding exons of the TRß gene were sequenced from gDNA extracted from PBLs and using primers and conditions described previously (9, 16). The oligonucleotide primers used for amplification and sequencing of the two exons containing nucleotide substitutions were as follows. For exon 4 of the TRß1 gene, primers were 5'-GCCTTCGAAAACTCTGCATCTCA-3' (sense) and 5'-CTTGTTGAAACACAT GATAATGGGCTA-3' (antisense) at 55 C annealing temperature, and those for exon 9 were 5'-CTGTATGTTGTTCCTGACTGGCAT-3' (sense) and 5'-GTGATTGGAATTAGCGCTAG ACAAGCA-3' (antisense) at 59 C annealing temperature. PCR products were confirmed by direct sequencing using ABI PRISM BigDye terminator cycle sequencing reading reaction kits (Applied Biosystem, Foster City, CA).

cDNA was prepared by reverse transcription of mRNA with the Superscript III first-strand synthesis system for RT-PCR (Life Technologies/Invitrogen, Carlsbad, CA) and random hexamers to sequence exons 9–10 of the TRß gene. The primers for amplification and sequencing were 5'-ACCAGATCATCCTCCTCAAAGG-3' (sense) and 5'-TGAATCCAGTCAGTCTAATCCTCG-3' (antisense). Annealing was at 58 C for 1 min and extension at 72 C for 1 min for each of the 35 cycles.

Genotyping

The mutation was confirmed in gDNA and cDNA by restriction fragment length polymorphism (RFLP) using the restriction endonuclease NlaIII (New England Biolabs, Beverly, MA), which cleaves only the mutant sequences at the site of the nucleotide substitution. The primers, 5'-GTGCGCTATGACCCAGAAAG-3' (sense) and 5'-AGGAGGGCTA CTTCAGTGTC-3' (antisense), amplify a 164-bp segment of exon 9 at 56 C annealing temperature. cDNA was amplified by a two-step PCR. The product of a first PCR amplification using primers located in exons 9 and 10 was used as template for a second PCR to amplify the 164-bp fragment of exon 9 as described above.

The sizes of fragments after restriction with NlaIII were 61, 55, and 48 bp for the mutant allele and 116 and 48 bp for the wild-type (WT) allele. Fragments were well separated on a 16% nondenaturing polyacrylamide gel at 100 V for 1 h.

To determine the relative amounts of mutant and WT alleles, ethidium bromide-strained gels were scanned, and the density of the respective bands was measured using Image J, version 1.34 S (Rasband, W. S., Image J, U.S. National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/ (18). Because the mutant allele generated two closely migrating bands, the combined densities were divided by two and corrected for molecular size (x 0.83). The total amount of combined mutant and WT alleles is represented by the density of the 48-kb band (see Fig. 5Go). Results are expressed as percentage of the mutant allele relative to the WT allele in heterozygous subjects.


Figure 5
View larger version (42K):
[in this window]
[in a new window]
  		FIG. 5. Genotyping by PCR-based RFLP analysis. All PCR products were 164 bp in size. After digestion with NlaIII, the WT allele produces two fragments of 116 and 48 bp and the mutant allele, three fragments of 61, 55, and 48 bp. cDNA isolated from PBLs of the affected father (I.1) and gDNA isolated from PBLs, and prostate tissue of the affected father have faint mutant 61- and 55-bp bands.

 
Haplotyping

All family members were assigned the TRß1 allele haplotypes using a PCR-based silent substitution of nucleotide 461 (TCG->TCA, S54S), which was found in the affected father. The products of PCR amplification using primers for exon 4, as described above, were determined by sequencing.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Clinical studies

We measured serum TSH at baseline and after administration of incremental doses of L-T3 to the father and 15 normal individuals. Serum TSH level of the father at baseline was 1.3 µU/ml. L-T3 doses of 50, 100, and 200 µg/d suppressed TSH to 46.2, 15.4, and 7.7%, respectively, whereas in control subjects TSH was suppressed to means ± SD of 9.6 ± 4.4, 3.6 ± 1.9, and 2.5 ± 1.7% of baseline (Fig. 2Go). Thus, response of the pituitary thyrotrophs to L-T3 in the father was reduced, compared with the normal subjects.


Figure 2
View larger version (12K):
[in this window]
[in a new window]
  		FIG. 2. Response of the pituitary thyrotrophs to L-T3. The father was given three incremental doses of L-T3, each for 3 consecutive days, as described in Subjects and Methods. The serum levels of T3 achieved were as expected, as was the reduction of FT4I. However, the suppression of TSH was much less pronounced than normal. Dot symbols indicate mean responses of control subjects and bars ± SD. The asterisk is the value observed in the father. Encircled asterisk indicates abnormal response.

 
The sensitivity of peripheral tissues to thyroid hormone was also assessed using the serum cholesterol, CK, ferritin, and SHBG as markers. The responses of the father’s peripheral tissues were not uniform. The stimulation of SHBG and suppression of cholesterol and CK were not different from those of control subjects, whereas ferritin failed to normally respond to L-T3 (Fig. 3Go). His resting pulse increased from 68 to 84 beats/min, whereas his weight declined by 1.5 kg (from 60.0 to 58.5 kg), both normal responses to the hormone (3).


Figure 3
View larger version (13K):
[in this window]
[in a new window]
  		FIG. 3. Response of peripheral tissues of the father to the administration of L-T3, as described in the legend to Fig. 2Go. Responses of SHBG, cholesterol, and CK were in the normal range, whereas ferritin increase was attenuated. Different dot symbols indicate mean responses of control subjects and bars ± SD. The asterisk is the value observed in the father. Encircled asterisk indicates abnormal response.

 
Genetic studies

We identified in the proposita (II.1) and her brother (II.2) a heterozygous mutation at codon 338 (nucleotide 1297 CGG->TGG), located in exon 9 of the TRß gene, which results in the replacement of the normal arginine with tryptophan (R338W). Sequencing of gDNA extracted from PBL of her affected father (I.1) showed a reduced amplification of the mutant allele, compared with the normal allele (Fig. 4Go). We obtained a second blood sample and additional tissues from the affected father. These included buccal mucosa cells, prostate tissue, and skin fibroblasts. gDNA extracted from the second blood sample, buccal mucosa, and prostate tissue showed the same results, namely low amounts of the mutant allele relative to the WT allele. However, no sequence abnormalities in exon 9 of TRß gene were detected in gDNA isolated from skin fibroblasts. Findings were similar in cDNA derived from the respective tissues. As shown in Fig. 4Go, both TRß gene alleles of the proposita’s mother (I.2) were WT.


Figure 4
View larger version (42K):
[in this window]
[in a new window]
  		FIG. 4. Sense and antisense sequences of the WT R388 (CGG) and mutant 338W (TGG) alleles. The tissue of origin for the shown sequences is underlined. Similar patterns were observed in gDNA and cDNA sequence of the listed tissues but not underlined. The proposita (II.1) and her affected bother (II.2) are heterozygous, whereas their mother (I.2) is normal; gDNA and cDNA isolated from the affected father (I.1) cultured skin fibroblasts are also normal. gDNA and cDNA isolated from PBLs and gDNA from prostate tissue and buccal mucosa of the father have a T in position 1297, but the peak height is substantially lower than that in his children.

 
The PCR/RFLP method was also used to identify the mutant allele in members of the family (Fig. 5Go). The mutation CGG->TGG in codon 338 creates an additional restriction site (61 and 55 bp) for NlaIII. gDNA extracted from PBLs and cDNA isolated from skin biopsy of the proposita showed the expected additional fragment, whereas these were absent in her mother’s gDNA. Similarly gDNA and cDNA isolated from cultured skin fibroblasts of the affected father had only the WT allele. In contrast, gDNA extracted from blood sampled on different occasions, from prostate tissue as well as cDNA isolated from second blood sample of the father showed a weak, though detectable, fragment generated by NlaIII. The average amount of the mutant allele in gDNA of the father extracted from PBL was 8.6%, and that from prostate was 3.9%, compared with 50% of WT in PBLs of the proposita.

To determine the transmission of the mutation to the proposita and her affected brother, family members were haplotyped for a silent substitution of nucleotide 461 (TCG->TCA, S54S) present in the father. As shown in Fig. 6Go, both the proposita and her brother inherited the mutant TRß1 allele from their father. Although samples from the parents of the affected father were not available because they were deceased, we could deduce that the mutation occurred de novo in the father during early embryonic life because it was present in some but not all lineages of somatic cells and in the germline (Table 1Go).


Figure 6
View larger version (21K):
[in this window]
[in a new window]
  		FIG. 6. Haplotyping of family members. Haplotypes are shown below each symbol of the pedigree, and identical alleles have the same shading. The affected father (I.1) and his children (II.1 and II.2) share the same mutant allele. The de novo mutation occurred on the paternal allele harboring the nucleotide 461A silent mutation.

 

View this table:
[in this window]
[in a new window]
  		TABLE 1. Relative abundance of the mutant allele in gDNA and cDNA of different tissues in members of the family

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
We studied a Turkish family with RTH. The proposita and her brother had TFTs characteristic of RTH, short stature, and psychiatric symptoms. The father had similar TFTs but no growth or psychiatric disturbances. The mother had a normal phenotype and TFTs. In the two siblings, we identified mutant TRß gene, R338W, previously reported (5, 9, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28). However, gDNA extracted from the father’s two different PBL preparations, buccal mucosa, and prostate tissue showed a lesser amount of the mutant, compared with the normal allele. More importantly, no sequence abnormalities were detected in gDNA isolated from skin fibroblasts. This was evident in cDNA obtained from the respective tissues and was also demonstrated by PCR/RFLP in both gDNA and cDNA.

These results demonstrate that the father has a mosaicism for the mutant TRß R338W because it was present in some lineages of somatic cells but not in skin fibroblasts. The transmission of the mutation to his children proves that it is also present in his germline, indicating that the mutation occurred de novo in his early embryonic life. The mutation R338W (CGG->TGG) has been identified in 25 different families (5, 9, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and unpublished data from our laboratory). This DNA site is likely to be prone to de novo mutation (eight of 25 families) because of its location in a mutagenic CpG dinucleotide hot spot (29). The presence of a single nucleotide difference (G/A 461) in the father, which was also found in his children, demonstrates that it was the paternal allele that underwent the R338W mutation.

The clinical presentation of RTH and the severity of hormone resistance are highly variable. The possibility of variable levels of expression of the mutant allele relative to the normal counterpart has been explored, but results have been inconsistent (30, 31). Somatic mutations in the TRß gene have been reported only in TSH-secreting pituitary tumors presenting as TSH-induced thyrotoxicosis (32, 33). As expected, our clinical studies showed that mosaicism resulted in a variable degree of RTH in different tissues. The thyrotrophs were resistant to thyroid hormone as evidenced by the reduced suppressibility of TSH by L-T3. Failure of ferritin to respond to L-T3 suggests hormonal resistance in red blood cells, spleen, and other tissues that regulate serum ferritin levels. In contrast, the normal responses of SHBG, cholesterol, and CK to L-T3 suggest that the hepatocytes express predominantly the WT-TRß. These results also provide an explanation for the difference in the father’s clinical manifestation, compared to his two children.

Potential mechanisms of non-TR-mediated RTH involve abnormalities at all steps in the mediation of thyroid hormone action (34). Defects in the thyroid hormone transporter MCT8 have been recently identified, but they do not produce a phenotype of RTH (35, 36). Another thyroid hormone transporter, LST-1, was not linked to the RTH phenotype in three families with non-TR RTH studied (Macchia, P. E., R. E. Weiss, and S. Refetoff, unpublished data). Aberrant alternative splicing was the defect causing pituitary RTH in one somatic TRß gene mutation (33). Mutations in the promoter of the TRß gene could reduce the level of gene expression; however, such a defect will produce RTH only in the homozygous state because subjects heterozygous for TRß gene deletion do not manifest RTH (8). Finally, based on mouse models of RTH (37, 38), search for mutations of coregulators in subjects with non-TR RTH have yielded negative results (39). Mosaicism has been reported in a small number of autosomal dominant disorders including pseudoachondroplasia (40), tuberous sclerosis (41), retinoblastoma (42), neurofibromatosis type 2 (43), familial isolated hyperparathyroidism (44), familial hypocalcemia (45), Albright hereditary osteodystrophy (46), and monogenic diabetes mellitus (47). The mosaicism rate for autosomal disorders is 6–19% (48). Thus, it is reasonable to speculate that TRß gene mutations could have been missed in some patients reported as having non-TR RTH. Often the degree of mosaicism is different among tissues, and the mutation might not be present in the tissue examined. Linkage analysis is also prone to miss the possibility of mosaicism because this method is based on allele inheritance and germline transmission (43, 44). Thus, this is of particular concern in disorders that are frequently sporadic and have increased rates of de novo mutations (49).

Our findings in this family are pertinent to RTH studies because they point to an issue not previously considered in patients with RTH in whom a mutation in TRß is not detected. Therefore, the examination of several different tissues should be considered in cases of putative non-TR RTH.


   Footnotes
 
This work was supported by Grants RR00055, RR18372, DK58281, DK17050, and DK20595 from the National Institutes of Health; a Ratchaburi Hospital Scholarship, Ratchaburi, Thailand (to S.M.); and a Howard Hughes Medical Institute Predoctoral Fellowship (to A.M.D.).

S.R. is Academic Associate for Quest Diagnostics (San Juan Capistrano, CA).

First Published Online June 27, 2006

Abbreviations: CK, Creatine kinase; FT4, free T4; FT4I, FT4 index; gDNA, genomic DNA; PBL, peripheral blood lymphocyte; RFLP, restriction fragment length polymorphism; RTH, resistance to thyroid hormone; TFT, thyroid function test; TG, thyroglobulin; TPO, thyroid peroxidase; TR, thyroid hormone receptor; TrT3, total reverse T3; TT4, total thyroxine; WT, wild type.

Received April 4, 2006.

Accepted June 16, 2006.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Refetoff S, DeWind LT, DeGroot LJ 1967 Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 27:279–294[Medline]
  2. Refetoff S 2005 Resistance to thyroid hormone. In: Braverman LE, Utiger RE, eds. Werner and Ingbar’s the thyroid: a fundamental and clinical text. 9th ed. Philadelphia: Lippincott, Williams and Wilkins; 1109–1129
  3. Refetoff S, Weiss RE, Usala SJ 1993 The syndrome of resistance to thyroid hormone. Endocr Rev 14:348–399[CrossRef][Medline]
  4. Beck-Peccoz P, Chatterjee VK 1994 The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 4:225–232[Medline]
  5. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD 1995 Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institute of Health Prospective Study. Ann Intern Med 123:572–583[Abstract/Free Full Text]
  6. Hayashi Y, Weiss RE, Sarne DH, Yen PM, Sunthornthepvarakul T, Marcocci C, Chin WW, Refetoff S 1995 Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-ß receptors? J Clin Endocrinol Metab 80:3246–3256[Abstract]
  7. Usala SJ, Bale AE, Gesundheit N, Weinberger C, Lash RW, Wondisford FE, McBride OW, Weintraub BD 1988 Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbAb gene. Mol Endocrinol 2:1217–1220[Abstract]
  8. Takeda K, Sakurai A, DeGroot LJ, Refetoff S 1992 Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-ß gene. J Clin Endocrinol Metab 74:49–55[Abstract]
  9. Adams M, Matthews C, Collingwood TN, Tone Y, Beck-Peccoz P, Chatterjee KK 1994 Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone: identification of thirteen novel mutations in the thyroid hormone receptor ß gene. J Clin Invest 94:506–515[Medline]
  10. Yoh SM, Chatterjee VKK, Privalsky ML 1997 Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptor and transcriptional corepressor. Mol Endocrinol 11:470–480[Abstract/Free Full Text]
  11. Liu Y, Takeshita A, Misiti S, Chin WW, Yen PM 1998 Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. Endocrinology 139:4197–4204[Abstract/Free Full Text]
  12. Weiss RE, Hayashi Y, Nagaya T, Petty KJ, Murata Y, Tunca H, Seo H, Refetoff S 1996 Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptors {alpha} or ß genes may be due to a defective co-factor. J Clin Endocrinol Metab 81:4196–4203[Abstract]
  13. Sadow P, Reutratkul S, Weiss RE, Refetoff S 2000 Resistance to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes. Curr Opin Endocrinol Diabetes 7:253–259[CrossRef]
  14. Vlaeminck-Guillem V, Margotat A, Torresani J, D’Herbomez M, Decoulx M, Wemeau JL 2000 Resistance to thyroid hormone in a family with no TRß gene anomaly: pathogenic hypotheses. Ann Endocrinol (Paris) 61:194–199[Medline]
  15. Parikh S, Ando S, Schneider A, Skarulis MC, Sarlis NJ, Yen PM 2002 Resistance to thyroid hormone in a patient without thyroid hormone receptor mutations. Thyroid 12:81–86[CrossRef][Medline]
  16. Pohlenz J, Weiss RE, Macchia PE, Pannain S, Lau IT, Ho H, Refetoff S 1999 Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor ß gene. J Clin Endocrinol Metab 84:3919–3928[Abstract/Free Full Text]
  17. Chrmczynski P, Sacchi N 1987 Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159[Medline]
  18. Abramoff MD, Magelhaes PJ, Ram SJ 2004 Image processing with Image J. Biophotonics Int 11:36–42
  19. Margotat A, Sarkissian G, Malezet-Desmoulins C, Peyrol N, Vlaeminck Guillem V, Wemeau JL, Torresani J 2001 Identification of eight new mutations in the c-erbAB gene of patients with resistance to thyroid hormone. Ann Endocrinol (Paris) 62:220–225[Medline]
  20. Hayashi Y, Sunthornthepvarakul T, Refetoff S 1994 Mutation of CpG dinucleotides located in the triiodothyronine (T3)-binding domain of the thyroid hormone receptor (TR) ß gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid hormone. J Clin Invest 94:607–615[Medline]
  21. Weiss RE, Weinberg M, Refetoff S 1993 Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor ß gene: analysis of 15 families. J Clin Invest 91:2408–2415[Medline]
  22. Mixon AJ, Parrilla SC, Ransom SC, Wiggs EA, McClaskey JH, Hauser P, Weintraub BD 1992 Correlations of language abnormalities with localization of mutations in the ß-thyroid hormone receptor in 13 kindreds with generalized resistance to thyroid hormone: Identification of four new mutations. J Clin Endocrinol Metab 75:1039–1045[Abstract]
  23. Sasaki S, Nakamura H, Tagami T, Miyoshi Y, Nogimori T, Mitsuma T, Imura H 1993 Pituitary resistance to thyroid hormone associated with a base mutation in the hormone-binding domain of the human 3,5,3'-triiodothyronine receptor-ß. J Clin Endocrinol Metab 76:1254–1258[Abstract]
  24. Mixson AJ, Renault JC, Ransom S, Bodenner DL, Weintraub BD 1993 Identification of a novel mutation in the gene encoding the ß-triiodothyronine receptor in a patient with apparent selective pituitary resistance to thyroid hormone. Clin Endocrinol (Oxf) 38:227–234[Medline]
  25. Lazarus JH, Gough J, Chatterjee VKK Terminal left ventricular failure in a patient with resistance to thyroid hormone. Proc Second International Workshop on Thyroid Hormone Resistance, 1995, Padua, Italy
  26. Ando S, Nakamura H, Sasaki S, Nishiyama K, Kitahara A, Nagasawa S, Mikami T, Natsume H, Genma R, Yoshimi T 1996 Introducing a point mutation identified in a patient with pituitary resistance to thyroid hormone (Arg 338 to Trp) into other mutant thyroid hormone receptors weakens their dominant negative activities. J Endocrinol 151:293–300[Abstract]
  27. Taniyama M, Ban Y, Momotani N, Makino F, Ito K 2001 Three Japanese patients from two families with generalized resistance to thyroid hormone with mutations in exon 9 of the thyroid hormone receptor ß gene. Intern Med 40:756–758[Medline]
  28. Platts A, Greenaway T, Parameswaran V 2001 Chronically elevated thyroid-stimulating hormone: resistance to thyroid hormone. Intern Med 31:430–431[CrossRef]
  29. Cooper DN, Krawczak M 1990 The mutation spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet 85:55–74[Medline]
  30. Mixon AJ, Hauser P, Tennyson G, Renault JC, Bodenner DL, Weintraub BD 1993 Differential expression of mutant and normal ß T3 receptor alleles in kindreds with generalized resistance to thyroid hormone. J Clin Invest 91:2296–2300[Medline]
  31. Hayashi Y, Janssen OE, Weiss RE, Murata Y, Seo H, Refetoff S 1993 The relative expression of mutant and normal thyroid hormone receptor genes in patients with generalized resistance to thyroid hormone determined by estimation of their specific messenger ribonucleic acid products. J Clin Endocrinol Metab 76:64–69[Abstract]
  32. Ando S, Sarlis NJ, Oldfield EH, Yen PM 2001 Somatic mutation of TRß can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 86:5572–5576[Abstract/Free Full Text]
  33. Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang MQ, Oldfield EH, Yen PM 2001 Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 15:1529–1538[Abstract/Free Full Text]
  34. Dumitrescu AM, Refetoff S 2006 Multiple etiologies for reduced sensitivity to thyroid hormone. Hot Thyroidology (www.hotthyroidology.com); 1–9
  35. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S 2004 A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 74:168–175[CrossRef][Medline]
  36. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP, Visser TJ 2004 Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 364:1435–1437[CrossRef][Medline]
  37. Weiss RE, Xu J, Ning G, Pohlenz J, Mallery BWO, Refetoff S 1999 Mice deficient in the steroid receptor coactivator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18:1900–1904[CrossRef][Medline]
  38. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR 2000 Thyroid hormone resistance and increased metabolic rate in the RXR-{gamma}-deficient mouse. J Clin Invest 106:73–79[Medline]
  39. Reutrakul S, Sadow PM, Pannain S, Pohlenz J, Carvalho GA, Macchia PE, Weiss RE, Refetoff S 2000 Search for abnormalities of nuclear corepressors, coactivators and a coregulator in families with resistance to thyroid hormone without mutations in thyroid hormone receptor ß or {alpha} genes. J Clin Endocrinol Metab 85:3609–3617[Abstract/Free Full Text]
  40. Ferguson HL, Deere M, Evans R, Rotta J, Hall JG, Hecht JT 1997 Mosaicism in pseudoachondroplasia. Am J Med Genet 70:287–291[CrossRef][Medline]
  41. Yates JRW, van Bakel I, Sepp T, Payne SJ, Webb DW, Navin NC, Green AJ 1997 Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet 6:2265–2269[Abstract/Free Full Text]
  42. Sippel KC, Fraioli RE, Smith GD, Schalkoff ME, Dryja TP 1997 Frequent somatic and germline mosaicism in retinoblastoma: relevance to genetic counseling. Am J Hum Genet 61:A16
  43. Bijlsma EK, Wallace AJ, Evans DGR 1997 Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet 34:934–936[Abstract]
  44. Villablance A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, The BT, Robinson BG, Larsson C 2004 Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41:e32
  45. Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE 2003 Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene. J Clin Endocrinol Metab 88:3674–3681[Abstract/Free Full Text]
  46. Aldred MA, Bagshaw P, Macdermot K, Casson D, Murch SH, Walker-Smith JA, Trembath RC 2000 Germline mosaicism for a GNAS1 mutation and Albright hereditary osteodystrophy. J Med Genet 37:e35
  47. Gloyn AL, Cummings EA, Edghill EL, Harries LW, Scott R, Costa T, Temple K, Hattersley AT, Ellard S 2004 Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the ß-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 89:3932–3935[Abstract/Free Full Text]
  48. Zlotogorn J 1998 Germline mosaicism. Hum Genet 102:381–386[CrossRef][Medline]
  49. Yossoufian H, Pyeritz RE 2002 Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 3:748–758[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/9/3471    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mamanasiri, S.
Right arrow Articles by Refetoff, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mamanasiri, S.
Right arrow Articles by Refetoff, S.
Related Collections
Right arrow Pediatric Endocrinology
Right arrow Thyroid

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals